Skip to main content
Erschienen in: Supportive Care in Cancer 7/2008

01.07.2008 | Original Article

Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients

verfasst von: Luciano de Souza Viana, José Carlos Serufo, Manoel Otávio da Costa Rocha, Renato Nogueira Costa, Roberto Carlos Duarte

Erschienen in: Supportive Care in Cancer | Ausgabe 7/2008

Einloggen, um Zugang zu erhalten

Abstract

Goals of work

This is a prospective and observational study comparing the efficacy of risk-assessment models in patients with neutropenic fever in a reference treatment center. The meaning of the complex infection was evaluated.

Materials and methods

Patients were recruited throughout a 9-month period. Inclusion criteria were histologic diagnosis of malignancy, neutropenic febrile secondary to chemotherapy and/or radiotherapy (absolute neutrophil count of <500/µl and axillary temperature ≥38°C), and ≥18 years of age.

Main results

Fifty-three febrile neutropenic patients were included. Twenty one of them were classified as low risk by the Multinational Association of Supportive Care in Cancer (MASCC) risk-index score. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of the MASCC risk-index scores were, respectively 87.9, 85.0, 90.6, 80.9, and 86.8%. None of the low-risk patients died, but four patients classified as low risk by the MASCC model developed serious medical complications during febrile neutropenic episodes. When we subtracted patients with complex infections from the group of patients with the MASCC risk-index score of ≥21, we got 15 patients that were classified as low risk by a proposed adjustment by complex infection (PACI) model. None of them developed serious medical complications. The sensitivity, specificity, PPV, NPV, and the accuracy of this new model were, respectively, 100, 75.0, 86.8, 100, and 90.6%.

Conclusion

The MASCC risk-index score had high sensitivity and specificity to predict the absence of complications, but the PACI model was better than MASCC for predicting the absence of complications in this febrile neutropenic patients.
Literatur
1.
Zurück zum Zitat Chamilos G, Bamias A, Efstathiou E et al (2005) Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer 103(12):2629–2635PubMedCrossRef Chamilos G, Bamias A, Efstathiou E et al (2005) Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer 103(12):2629–2635PubMedCrossRef
2.
Zurück zum Zitat Cherif H, Johansson E, Bjorkholm M et al (2006) The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica 91(2):215–222PubMed Cherif H, Johansson E, Bjorkholm M et al (2006) The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica 91(2):215–222PubMed
3.
Zurück zum Zitat Donowitz GR, Maki DG, Crnich CJ, et al (2001) Infections in the Neutropenic Patient - New Views of an Old Problem. In: ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, 43TH., 2001, Orlando. Education Program Book: Hematology (Am Soc Hematol Educ Program):113–139 Donowitz GR, Maki DG, Crnich CJ, et al (2001) Infections in the Neutropenic Patient - New Views of an Old Problem. In: ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, 43TH., 2001, Orlando. Education Program Book: Hematology (Am Soc Hematol Educ Program):113–139
4.
Zurück zum Zitat Elting LS, Rubenstein EB, Rolston KV et al (1997) Outcomes of bacteremia in patients with cancer and neutropenia: Observations from two decades of epidemiological and clinical trials. Clin Infect Dis 25(2):247–259PubMedCrossRef Elting LS, Rubenstein EB, Rolston KV et al (1997) Outcomes of bacteremia in patients with cancer and neutropenia: Observations from two decades of epidemiological and clinical trials. Clin Infect Dis 25(2):247–259PubMedCrossRef
5.
Zurück zum Zitat Escalante CP, Weiser MA, Manzullo E et al (2004) Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients. Support Care Cancer 12(9):657–662PubMed Escalante CP, Weiser MA, Manzullo E et al (2004) Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients. Support Care Cancer 12(9):657–662PubMed
6.
Zurück zum Zitat Hughes WT, Armstrong D, Bodey GP et al (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34(6):730–751PubMedCrossRef Hughes WT, Armstrong D, Bodey GP et al (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34(6):730–751PubMedCrossRef
7.
Zurück zum Zitat Kern WV (2006) Risk assessment and treatment for low-risk patients with febrile neutropenia. Clin Infect Dis 42(4):533–540PubMedCrossRef Kern WV (2006) Risk assessment and treatment for low-risk patients with febrile neutropenia. Clin Infect Dis 42(4):533–540PubMedCrossRef
8.
Zurück zum Zitat Klastersky J, Paesmans M, Rubenstein EB et al (2000) The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18(16):3038–3051PubMed Klastersky J, Paesmans M, Rubenstein EB et al (2000) The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18(16):3038–3051PubMed
9.
Zurück zum Zitat Nijhuis CO, Kamps WA, Daenen SM et al (2005) Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. J Clin Oncol 23(30):7437–7444CrossRef Nijhuis CO, Kamps WA, Daenen SM et al (2005) Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. J Clin Oncol 23(30):7437–7444CrossRef
10.
Zurück zum Zitat Paesmans M (2000) Risk factors assessment in febrile neutropenia. Int J Antimicrob Agents 16(2):107–111PubMedCrossRef Paesmans M (2000) Risk factors assessment in febrile neutropenia. Int J Antimicrob Agents 16(2):107–111PubMedCrossRef
11.
Zurück zum Zitat Sipsas NV, Bodey GP, Kontoyiannis DP (2005) Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer 103(6):1103–1113PubMedCrossRef Sipsas NV, Bodey GP, Kontoyiannis DP (2005) Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer 103(6):1103–1113PubMedCrossRef
12.
Zurück zum Zitat Rolston KV (2003) Oral antibiotic administration and early hospital discharge is a safe and effective alternative for treatment of low-risk neutropenic fever. Cancer Treat Rev 29(6):551–554PubMedCrossRef Rolston KV (2003) Oral antibiotic administration and early hospital discharge is a safe and effective alternative for treatment of low-risk neutropenic fever. Cancer Treat Rev 29(6):551–554PubMedCrossRef
13.
Zurück zum Zitat Rolston KV (1999) New trends in patient management: Risk-based therapy for febrile patients with neutropenia. Clin Infect Dis 29(3):515–521PubMedCrossRef Rolston KV (1999) New trends in patient management: Risk-based therapy for febrile patients with neutropenia. Clin Infect Dis 29(3):515–521PubMedCrossRef
14.
Zurück zum Zitat Talcott JA, Finberg R, Mayer RJ et al (1988) The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 148(12):2561–2568PubMedCrossRef Talcott JA, Finberg R, Mayer RJ et al (1988) The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 148(12):2561–2568PubMedCrossRef
15.
Zurück zum Zitat Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer 12(8):555–560PubMedCrossRef Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer 12(8):555–560PubMedCrossRef
Metadaten
Titel
Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients
verfasst von
Luciano de Souza Viana
José Carlos Serufo
Manoel Otávio da Costa Rocha
Renato Nogueira Costa
Roberto Carlos Duarte
Publikationsdatum
01.07.2008
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 7/2008
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-007-0347-3

Weitere Artikel der Ausgabe 7/2008

Supportive Care in Cancer 7/2008 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.